Clinical trials: Time in Range
Type 2 Diabetes
IGNITE (Impact of Glucose moNitoring and nutrItion on Time in rangE)
The purpose of this study is to learn whether there is a difference in the amount of time glucose (blood sugar) stays within a target range (glucose 70 - 180 mg/dl) when using either continuous glucose monitoring (CGM) or…
- Trial name
- IGNITE (NCT05516797)
- Testing
- Continuous Glucose Monitoring (CGM)
- Where
- United States
- Volunteers
- 178 people
- Sponsor
- HealthPartners Institute
Type 1 Diabetes
Ultrarapid Insulin Administered by a Bihormonal Closed Loop System in Patients With Type 1 Diabetes
The main objective is to determine the efficacy of Lyumjev (insulin) in a bi-hormonal reactive closed loop system for automated glucose regulation (artificial pancreas; AP®) in patients with diabetes mellitus type 1.
- Trial name
- FAST 1 (NCT05508061)
- Testing
- Insulin Lispro Cartridge [Lyumjev], Insulin Lispro Cartridge
- Where
- 3 sites in Netherlands
- Volunteers
- 12 people
- Sponsor
- Inreda Diabetic B.V.
Diabetes Mellitus, Type 1
Study Comparing Prandial Insulin Aspart vs. Technosphere Insulin in Patients With Type 1 Diabetes on Multiple Daily Injections: Investigator-Initiated A Real-life Pilot Study-STAT Study
This is an investigator-initiated, prospective, randomized, multicenter, parallel, open-label, pilot clinical trial evaluating the efficacy of TI for PPBG, PPGE, and time-in-range on CGM download in patients with T1D.
- Trial name
- STAT (NCT03143816)
- Testing
- Technosphere insulin
- Where
- United States
- Volunteers
- 60 people, healthy volunteers welcome
- Sponsor
- University of Colorado, Denver
Type 2 Diabetes
A Study of Mealtime Insulin LY900014 in Participants With Type 2 Diabetes Using Continuous Glucose Monitoring (PRONTO-Time in Range)
This study is being done to evaluate glycemic control in participants with type 2 diabetes who are taking mealtime insulin LY900014 in combination with long-acting insulin glargine.
- Trial name
- NCT04605991
- Testing
- LY900014, Insulin Glargine
- Where
- 32 sites in United States, Puerto Rico
- Volunteers
- 187 people
- Sponsor
- Eli Lilly and Company
Type 1 Diabetes
A Study of LY900014 and Insulin Degludec in Participants With Type 1 Diabetes
In this study, participants with type 1 diabetes (T1D) will take the study drug LY900014 and insulin degludec. The reason for this study is to evaluate the amount of time with glucose values within target range.
- Trial name
- NCT04585776
- Testing
- LY900014, Insulin Degludec
- Where
- 3 sites in United States
- Volunteers
- 31 people
- Sponsor
- Eli Lilly and Company
Atrial Fibrillation, Venous Thromboembolism
Prothrombin Times Outside the Therapeutic Range in Otherwise Stable Patients
Warfarin is very effective for the prevention of blood clots (thrombosis). A test of coagulation, the prothrombin time (PT) is used to monitor the effect.
- Conditions
- Atrial Fibrillation, Venous Thromboembolism, Ischemic Stroke, Myocardial Infarction
- Trial name
- FORESPEAK-0 (NCT00814177)
- Testing
- warfarin
- Where
- Canada
- Volunteers
- 160 people
- Sponsor
- Hamilton Health Sciences Corporation
Type 1 Diabetes, Type 1 Diabetes Mellitus With Hypoglycemia
Maximising Time With a Normal Blood Glucose to Restore the Glucagon Response in Type 1 Diabetes
Almost all people who have had type 1 diabetes for 5 years have a defect in secretion of the hormone Glucagon. This hormone is involved in the body's response to low blood glucose (hypoglycaemia).
- Conditions
- Type 1 Diabetes, Type 1 Diabetes Mellitus With Hypoglycemia, Hypoglycemia, Hypoglycemia Unawareness
- Trial name
- NCT04614168
- Testing
- Stepped hyperinsulinaemic-hypoglycaemic clamp study, Insulin pump, Continuous glucose monitor
- Where
- United Kingdom
- Volunteers
- 24 people
- Sponsor
- University of Edinburgh
Type 1 Diabetes, Obesity
ADJUnct Semaglutide Treatment in Type 1 Diabetes
The purpose of this study is to assess the use of once weekly semaglutide injection in inadequately controlled obese adults with type 1 diabetes (T1D) using FDA-approved hybrid closed-loop therapies.
- Trial name
- ADJUST-T1D (NCT05537233)
- Testing
- Semaglutide
- Where
- 4 sites in United States
- Volunteers
- 115 people
- Sponsor
- Viral N. Shah
ICU, Dysglycemia
Glucose Time-In-Range Development Evaluation
The study will evaluate patients requiring frequent glucose monitoring in a Surgical ICU. The study population includes surgical critical care patients who require blood glucose monitoring.
- Trial name
- GIDE (NCT03670017)
- Testing
- OptiScanner® 5000 Glucose Monitoring System
- Where
- United States
- Volunteers
- 68 people
- Sponsor
- Washington University School of Medicine
Type 1 Diabetes, Hypoglycemia
CGM Use in Poorly Controlled Youth With Type 1 Diabetes
The purpose of this prospective study is to determine if trial use of a Dexcom G6 CGM system for a 10 day wear period in high risk, poorly controlled pediatric Type 1 diabetes patients increases uptake of personal CGM use, and…
- Conditions
- Type 1 Diabetes, Hypoglycemia, High Blood Sugar
- Trial name
- IMPaCT (NCT04721145)
- Testing
- Dexcom G6 Continuous Glucose Monitor
- Where
- United States
- Volunteers
- 26 people
- Sponsor
- Johns Hopkins University
Tourniquets, Knee Arthroplasty, Total
Tourniquet Pressure in Primary Total Knee Arthroplasty
This proposed novel randomized control trial (RCT) seeks to address this gap in TKA protocol by gaining a better understanding of the relationship between tourniquet pressure and time, and intraoperative performance and…
- Conditions
- Tourniquets, Knee Arthroplasty, Total, Knee Replacement, Total
- Trial name
- NCT02830087
- Testing
- Tourniquet Cuff Pressure
- Where
- 2 sites in United States
- Volunteers
- 21 people, healthy volunteers welcome
- Sponsor
- Wake Forest University Health Sciences
Type 2 Diabetes Mellitus
Effect of Soliqua 100/33 on Time in Range From Continuous Glucose Monitoring in Insulin-naive Patients With Very Uncontrolled Type 2 Diabetes Mellitus
The purpose of the study was to demonstrate if iGlarLixi (Soliqua 100/33) would improve glycemic control (as measured by Time in Range) and glycemic variability in participants with very uncontrolled (HbA1c ≥ 9%) type 2 Diabetes…
- Trial name
- Soli-CGM (NCT05114590)
- Testing
- Insulin glargine/Lixisenatide
- Where
- 18 sites in United States
- Volunteers
- 124 people
- Sponsor
- Sanofi
Type 2 Diabetes
My Diabetes Study - CGM Initiation Approach & Time In Range
This study includes two phases. The purpose of Phase 1 of this study is to understand if there is a difference between two ways of introducing a continuous glucose monitor (CGM) to people with type 2 diabetes (T2D).
- Trial name
- NCT05928572
- Testing
- CGM initiation approach
- Where
- United States
- Volunteers
- 159 people
- Sponsor
- Holly Willis
Management of Anticoagulation
Improved Time in Therapeutic Range With Patient Self-Testing of Their INR Compared to Usual Care
Patients who receive a mechanical heart valve to replace a diseased heart valve must take an anticoagulation medicine the rest of their lives, and monitor their level of anticoagulation.
- Trial name
- NCT00703963
- Testing
- INRatio monitor by Hemosense, Usual Care
- Where
- United States
- Volunteers
- 200 people, healthy volunteers welcome
- Sponsor
- Mayo Clinic